Introduction allogeneic origin are presented by self antigen presenting cells (APCs) (Figure 1 ). These peptides are derived from The introduction of cyclosporin in the early 1980s led to donor MHC molecules, presumably after being shed a dramatic improvement of transplant survival rates from the allograft into the recipient's circulation. The mainly through a reduction of acute rejection episodes molecules are internalized by the recipient's APCs, proearly after transplantation. The long term decline in graft cessed and presented on the cell surface by self MHC function, however, was not significantly influenced as class II molecules. The T-cells of the recipient are activindicated by a virtually unchanged half life of 7-8 years ated after recognizing this combined structure of a forfor kidney transplants [1] . Thus a main focus of trans-eign peptide presented in the groove of a self MHC plantation research remains to elucidate the mechanisms molecule [6, 7] . In the case of indirect allorecognition the that lead to this perpetual long term loss of kidney activated CD4+ T-cells mediate the effector mechanisms allograft function. It is now believed that both immuno-of allograft rejection (cell-mediated cytotoxicity, antilogical as well as non-immunological factors 'injure' the body-dependent cytotoxicity, delayed-type hypersensitallograft resulting in functional and morphological ivity reactions/inflammation and natural killing) by changes known as chronic allograft failure/rejection [2] . providing the necessary cytokines for the activation of 
The direct and the indirect pathways of
Recent work by several investigators using synthetic, allorecognition MHC derived peptides indicates that this particular way of allorecognition occurs in animals and in humans. The central immunological event that initiates allograft DeKoster et al. [8] were first to show that human T-cells rejection is the recognition of allo-MHC-molecules by recognize processed allo-MHC in a self restricted manner. recipient T-cells [3, 4] . The allorecognition process was T-cell clones primed by a HLA-DR3 derived peptide long considered to occur exclusively in a direct fashion, were able to proliferate to allo-MHC (HLA-DR3) molecwhere T-cells recognize intact allo-MHC-molecules on ules on HLA-DR3/DP3 cells. the surface of donor cells. Then, in the early 1980s, Liu and Suciu-Foca [9] studied a larger number of Lechler and Batchelor [5] suggested an additional different synthetic peptides and demonstrated that route of T-cell recognition of alloantigen. They human responder T-cells primed in vitro by allogeneic observed that MHC-incompatible rat kidney allografts, DR1 expressing cells recognize and proliferate to synthetic MHC peptides derived from the hypervariable that were dendritic-cell-depleted after being 'parked' domaine of the DRb1*0101 molecule when presented by in intermediate hosts could be rejected in certain donor/ self APCs. Liu's work brought about another important recipient combinations after retransplantation.
observation: the frequency of T-cells taking part in the A decade later major advances in the field of biochemindirect mode of presentation is about 100-fold lower istry, e.g. the discovery of the structure of MHC class I than that of T-cells recognizing the whole MHC molecule and II molecules, new insights into antigen processing directly [10] . This must be kept in mind when one and presentation, and the ability to synthesize peptides interprets results of clinical studies that investigate the corresponding to known sequences of MHC molecules, indirect mode of presentation in humans. provide insights into the mechanisms underlying this second way of allorecognition. The indirect pathway of allorecognition resembles that of nominal antigens (e.g. What is the role for the indirect pathway of allorecognition in transplant recipients? mismatched renal allograft recipients proliferated in What is the role for the indirect pathway of vitro to two of five overlapping peptides derived from allorecognition in acute allograft rejection?
HLA-A2 [11] . In another study, Susskind et al. have shown that CD4+ cytolytic T cells of transplant The occurrence of the indirect pathway during acute patients are able to recognize and to be sensitized by allograft rejection has been demonstrated earlier in HLA Class I allopeptides of donor origin [12] . rat heart and kidney transplant models [13, 14, 19 ]. Similar to a large number of animal studies First data supporting an activation of the indirect demonstrating a role of the indirect pathway of pathway of allorecognition during human allograft allorecognition in vivo during rejection of skin and rejection were recently published. In human cardiac vascularized allografts [13] [14] [15] , there is mounting allograft recipients undergoing acute rejection, Liu evidence that it may also play a role in human organ et al. [20] were able to detect circulating T-cells, transplantation. But studies in patients are still com-specific for a DR1 peptide in DRb*1101 recipients of plicated by a variety of problems. First, we lack an hearts from DRb*0101 donors. They further demonappropriate assay to detect the relatively low fre-strated that these cells can be found prior to and quency of all alloreactive T-cells activated by the during acute and chronic rejection. In another series indirect pathway. Given the complexity of the HLA-investigating 32 cardiac allograft recipients with system and differently processed class I and class II different MHC class II donor/recipient combinations, MHC peptides, it is clear that an undefined number episodes of acute rejection were strongly associated of variable peptide/MHC complexes can activate with T-cell proliferation to synthetic peptides corresdifferent sets of T-cells. At the moment we only test ponding to the hypervariable regions of the misfor T-cell proliferation to a limited number of matched HLA-DR antigens [16 ] . The T-cell response arbitrarily synthesized peptides. Thus we may miss was restricted by a single HLA-DR antigen and additional T-cell clones, which are also activated directed against one immunodominant peptide, but through the indirect pathway and may underestimate during subsequent rejection episodes, the second the contribution of the indirect pathway to the total HLA-DR antigen was similarly able to elicit allopepalloimmune response. In addition Liu et al. [16 ] tide reactivity. They found that during repetitive found a 10-to 50-fold higher frequency of allopeptide rejection episodes, the alloreactive T-cell repertoire reactive T-cells within the rejecting organ, which changes, suggesting an intermolecular spreading [16 ] . remains undetected when looking at the frequency in This has to be kept in mind, when strategies to the systemic circulation. This methodological problem interfere with the presentation of allopeptides will be might be a reason for undetectable or seemingly low developed. It may not be sufficient to target a single precursor frequency of alloreactive T-cells in trans-MHC molecule or else a particular MHC/peptide planted patients [17, 18] . Nevertheless there is increascombination to prevent activation of the alloreactive ing evidence for an important role of the indirect pathway during rejection episodes.
T-cell repertoire.
peptide (residues 75-84), derived from HLA-B27 has
What is the role for the indirect pathway of already been tested in a small phase II clinical trial in allorecognition in chronic allograft rejection?
kidney allograft recipients. It was shown that this peptide is able to reduce peripheral blood NK cell A significant role of the indirect pathway of allorecog-cytotoxicity, but the mechanisms leading to the allele nition has long been discussed for chronic rejection, nonspecific inhibition of alloimmune response are still but indirect evidence for its presence in chronic allo-unknown [29] . graft rejection in humans was only recently published.
Until we can use synthetic peptides as immunotheraIts involvement was suggested in studies looking at peutics to prevent or treat allograft rejection in humans precursor frequencies of directly primed T-cells, soluble we need to elucidate further the mechanisms of cyto-HLA antigens, and proliferation to synthetic MHC-solic protein degradation, peptide transport systems, peptides. In limiting dilution analysis Mason et al.
[21] intracellular peptide assembly and peptide binding and studied the precursor frequencies of alloreactive T-cells gain more insight into possible immunodominant pepdirectly primed against the donor MHC antigens in tide epitopes that could serve as suitable targets for a kidney transplant patients, who had lost their graft. In possible and economically reasonable peptide therapy. a significant number of patients, who lost the graft If we are able to resolve these issues in the future, more than 2 years post-transplantation, directly primed peptide therapy could help to achieve better long term alloreactive T-cells could not be detected. Thus a role survival rates in organ transplantation and to reach for an alternate rejection mechanism, e.g. the indirect the ultimate goal of transplantation medicine, i.e. pathway was suggested. Reed et al. [22] examined tolerance induction. heart transplant patients and found an increased risk for the development of transplant-related coronary artery disease for patients with persistent donorderived soluble HLA antigens for more than 26 weeks References post-transplantation. These donor MHC molecules, 
Control of ligand availability by serum vitamin-D-binding protein (DBP)
The concentration of ligand in the target cell that is available for VDR binding will be determined by the rate of uptake into the cell and the rate of catabolism within the cell. In vivo, the rate of clearance of the ligand from the circulation will be an important factor. Clearance rate and uptake are known to be controlled to a large degree by the serum vitamin-D these data points, and replotted the activity data, they found that the induction of the 24-hydroxylase was VDR with TFIIB and with several coactivators, includ-dependent on the concentration of free, not total, ing steroid receptor coactivator 1 (SRC1), receptor 1,25(OH ) 2 D 3 ( Figure 3 ). Analogues with low DBP interacting protein 140 (RIP140) and nuclear coactiv-affinity have a higher fraction in the unbound state ator 62 (NcoA-62), have been reported. While our and have been shown to have greater accessibility than current knowledge of the control of gene transcription 1,25(OH ) 2 D 3 to target cells both in vitro and in vivo. Figure 1 , the mechan-Overall, DBP acts as a sink for vitamin D compounds ism will likely be much more complex than the simple and likely plays an important role in guarding against model shown here. A more complete treatment of vitamin D intoxication. With respect to 1,25(OH ) 2
-mediated gene transcription can be and its analogs, those with high DBP affinity have found in recent reviews [1, 2] . long half-lives and are delivered slowly to target cells, There are a number of factors that determine the while those with low DBP affinity can achieve higher amount of transcriptional activity produced by vitamin cellular levels for a much shorter duration. D compounds. These are illustrated in Figure 2 .
An example of how these altered pharmacokinetics Perhaps the most important determinants of vitamin can influence the biological profile of a vitamin D D action are the intracellular levels of the ligand and analogue is the selectivity of 22-oxa-1,25(OH ) 2 D 3 the VDR content, which together will determine the (OCT ) on parathyroid hormone (PTH ) secretion. On amount of activated, liganded receptor produced. The the one hand, the DBP affinity of OCT is 500 times factors that affect the ligand availability and VDR lower than that of 1,25(OH ) 2 D 3 resulting in more levels are discussed below. In addition, there is now rapid clearance and a lower maximal circulating level evidence that structural differences in vitamin D anaof the analog following injection. On the other hand, logues may produce distinct ligand-dependent conformational changes in the VDR which could influence the peak levels of OCT within the parathyroid glands and intestine are greater than those of 1,25(OH ) 2 D 3 , chain of the molecule. This is catalyzed by a single but decrease quickly following clearance of the analog. enzyme, the vitamin D 24-hydroxylase, and involves This 'pulse' of OCT produces only transient increases successive oxidations of carbons 24 and 23 followed in intestinal calcium absorption and bone mobilization by oxidative cleavage of the side chain to form [4] , but the same short exposure to the parathyroid calcitroic acid, the final water-soluble metabolite glands produces a prolonged suppression of PTH gene of 1,25(OH ) 2 D 3 . This enzyme is highly inducible by expression [5] . Thus, the differences in the duration of 1,25(OH ) 2 D 3 and its analogues and acts as an attenuthe calcemic responses vs PTH suppression lead to a ator of vitamin D action. An example is shown in greater effect of OCT on the parathyroid glands. Figure 4 . In their study, Zhao et al. [6 ] assessed the anti-proliferative effect of 1,25(OH ) 2 D 3 and an analogue, KH1060, on the breast cancer cell line, MCF-7.
Catabolic inactivation
Both compounds inhibited [3H ]thymidine incorporation into these cells in a dose-dependent manner, although the analogue was more active. The effectAn important attenuator of vitamin D action in target iveness of these compounds was enhanced significantly cells is catabolic inactivation. In all target cells, the major route of catabolism is oxidation of the side when the 24-hydroxylase was blocked by the cyto- and its analog KH1060 on MCF-7 breast cancer cells was measured in the absence or presence of the cytochrome P 450 inhibitor, ketoconazole. Blocking the catabolic enzyme (24-hydroxylase) enhanced the antiproliferative activity. Right, the ratio of the ED50 in the presence (+keto) vs absence (−keto) of ketoconazole. The activity is enhanced by ketoconazole in all cases, but the variation between analogs likely reflects differences in their rates of catabolism. From Zhao et al. [6 ] .
chrome P 450 inhibitor ketoconazole. The ratios of the from the study of Denda et al. [8] which noted that the decreased VDR in the parathyroid glands of uremic potencies of several vitamin D analogues in the presence vs absence of ketoconazole are shown in the right-rats was highly correlated with the circulating levels of 1,25(OH ) 2 D 3 . Administration of low doses of hand panel of Figure 4 . The different ratios are most likely due to differences in the rates of their catabolism 1,25(OH ) 2 D 3 or the analogue OCT to uremic rats restored VDR levels. Importantly, VDR mRNA was of each analogue. Thus, differential rates of catabolism, possibly in a cell-specific manner, may contribute to not different in these groups suggesting that, under these conditions, the regulation of parathyroid VDR the unique biological profiles of vitamin D analogues. levels was through ligand stabilization.
The mechanism for degradation of the VDR has
Vitamin D receptor regulation
only recently been addressed. Masuyama et al. [9] documented the direct interaction of the VDR with SUG1, a component of the proteasome. The proAnother very important determinant of transcriptional teasome is a large complex that is known to degrade activity in a target cell is the content of the vitamin D many cellular proteins, especially those that have receptor ( VDR). The content of the VDR will be been targeted for destruction through derivatization determined by both the rate of synthesis and the rate by ubiquitination. Using proteasome inhibitors, of degradation. Both of these are under regulation. In Masuyama et al. confirmed that the VDR is degraded addition, the VDR may be bound to calreticulin, a by the proteasome. The role of SUG1 binding in this calcium-binding protein that recognizes the nuclear process is currently under investigation, but it is clear translocation motif in many steroid receptors, and that its binding to the VDR is 1,25(OH ) 2 D 3 dependent. rendered inactive (see Figure 2 ). The regulation of Thus, ligand binding both protects the VDR from VDR levels has been studied in detail for many target degradation and promotes association with a proteasocells both in vivo and in cell culture. Many of the mal subunit. It has been proposed that SUG1 may regulators are cell-or tissue specific and there may be target the VDR for degradation following the initiation differences between species. A thorough review of this of gene transcription ( Figure 5 ). The ability of vitamin topic is beyond the scope of this article.
D analogues to promote SUG1 interaction and/or The most ubiquitous regulator of the VDR is stabilize the VDR is an important area of future 1,25(OH ) 2 D 3 . Ligand-dependent upregulation can investigation. occur through at least two mechanisms. In select tissues (e.g. parathyroid glands and kidney, but not intestine) 1,25(OH ) 2 D 3 upregulates VDR mRNA, possibly indir-
Post-translational modification of the VDR
ectly through changes in calcium. However, in virtually all cell types, 1,25(OH ) 2 D 3 increases VDR protein through ligand-dependent stabilization. Studies in vitro The VDR is a phosphoprotein and ligand binding has been shown to promote hyperphosphorylation of the [7] have shown that the presence of 1,25(OH ) 2 D 3 greatly increases the cellular half-life of the VDR. In receptor. Phosphorylation occurs at several loci and is mediated by various protein kinases. Phosphorylation vivo evidence for ligand-dependent stabilization comes extracts, but more recent studies have shown that addition of fractionated uremic plasma ultrafiltrate to cultured cells blunts the transcriptional activity of 1,25(OH ) 2 D 3 . It has been postulated that components in the uremic serum react covalently with the VDR at or near the DNA-binding domain.
Ligand-dependent VDR conformation
Crystallographic data indicate that a conserved a-helix near the C-terminus of steroid receptors undergoes a dramatic conformational shift upon ligand binding. scriptional complex including coactivators and TFIIB. Removal of the AF2 domain eliminates the transcriptional activity of 1,25(OH ) 2 D 3 without affecting ligand by protein kinase C (PKC ) (at serine 51) and PKA binding. However, Peleg et al. [11] have characterized appear to decrease VDR activity, while phosphoryl-several vitamin D analogues that are active even with ation by casein kinase (at serine 208) may enhance receptors lacking the AF2 domain. These analogues, VDR activity. Therefore, the nuclear actions of with the 20-epi configuration, appear to induce a 1,25(OH ) 2 D 3 may be modulated by agents acting at distinct VDR conformation as evidenced by their abilthe cell surface that activate protein kinase cascades. ity to partially protect the VDR from proteolysis. The This provides a means of cross-talk between vitamin unique VDR conformation induced by these analogs D and other hormonal systems. In addition, promoted a tighter association with RXR and a VDRE 1,25(OH ) 2 D 3 itself has been shown to rapidly activate as shown in Figure 6 . These findings emphasize the PKC through interaction with a cell-surface receptor importance of ligand structure on the conformation distinct from the nuclear VDR. A number of vitamin and activation of the VDR. D analogues have been shown to act differently to 1,25(OH ) 2 D 3 on the cell-surface receptor which could alter their genomic activity.
Regulation of transcriptional cofactors
Post-translational modification of the VDR in renal failure has been demonstrated by Hsu and Patel [10] . Vitamin D action could also be controlled by changes in the nuclear levels of the other components of the They reported that substances in uremic plasma ultrafiltrate can modify the VDR in a manner that disrupts transcriptional complex. However, nearly all of these proteins act as cofactors for other steroid receptors DNA binding. This was first demonstrated in cell-free and transcription factors, and altered levels would not 215: 223-228 affect the vitamin D system exclusively. A recent report 3 . Bikle DD, Gee E. Free, and not total, 1,25-dihydroxyvitamin D demonstrated reduced RXR levels in hyperplastic pararegulates 25-hydroxy D metabolism by keratinocytes. thyroid glands [12] enhanced, and a new equilibrium is found, however, at the expense of a loss of the calcium content in the bone. The end-point is hyperparathyroidism; the degree of this PTH hypersecretion may, however, largely differ from patient to patient, and within the same patient, from time-point to time-point in his/her evolution.
This imbalance is further affected by phosphate; renal failure causes phosphate retention, which in turn causes serum calcium to decrease, with the abovementioned consequences on calcitriol and PTH. In addition, phosphate itself also decreases calcitriol and increases PTH directly or indirectly [2] .
Curiously enough, several studies point to the fact that at the initiation stage of chronic renal failure, without supplementation of vitamin D analogues, calcitriol levels remain normal; in spite of this, PTH is elevated [3] . This data suggests the development of a certain degree of vitamin D resistance, as both the metabolic degradation of calcitriol and the inhibition of PTH secretion are regulated by calcitriol. These findings have, however, not consistently been confirmed [2, 4] , but this might be attributed to differences in patient selection, e.g. with regard to kidney function.
Several additional arguments point in the direction of calcitriol resistance in renal failure. Already in Fig. 1 . The normal sequence of the cellular receptor-mediated association with moderate defects of renal function, response to active vitamin D analogues. Impaired response to intestinal absorption of Ca2+ is decreased and whole-vitamin D in uraemia could be the consequence of disturbances at body retention of Ca2+ is increased [5] . In response each level of the genomic pathway. to increasing supplements of calcitriol, urinary calcium remains lower in early renal failure, compared to Decreased calcitriol receptor content healthy subjects [3] . Also in rats with moderate renal failure (reduction of GRF <50%), PTH increases It is of note that under normal conditions calcitriol compared to sham-treated rats with normal renal funcupregulates its own receptor, i.e. increasing serum tion, in spite of identical serum calcitriol levels [6 ] .
calcitriol induces an increase of VDR. VDR content All these data suggests that the response to calcitriol in uraemia has most frequently been studied in parais depressed, even if the fall in calcitriol levels normally thyroid glands. A decrease in VDR of parathyroid occuring with renal failure can be prevented. Calcitriol glands has been demonstrated in the rat [7] , the dog exerts its biological actions through binding with the [8] , and in men [9] . Similar data were also reported calcitriol receptor, which has two functional domains, for human peripheral blood mononuclear cells [10] one hormone binding and one DNA-binding. The DNA-binding domain has similarities to that of other and rat intestine [11] . steroid hormone receptors (e.g. glucocorticoid, oestroSzabo et al. could not confirm this decrease in VDR gen, thyroid, and retinoic acid receptors). After com-expression in parathyroid glands of uraemic patients plexation of calcitriol with the vitamin D receptor [12] . The reason for this inconsistency remains unclear. ( VDR), binding occurs with the DNA of vitamin-D-One of the reasons could be that in the studies by responsive elements ( VDREs-e.g. osteocalcin, osteo-Szabo et al., protease inhibitors were used in the pontin, 9K calcium binding protein gene), which are experimental set-up, preventing proteolytic degradapresent in vitamin D responsive genes.
tion of the receptor during its preparation from the Impaired response to vitamin D at the receptor level uraemic sample. This approach had not been followed could be the consequence of: (i) decreased binding of in earlier studies. However, later studies, where proteocalcitriol to the VDR; (ii) decreased expression of the lysis was prevented in a similar way as in the study by VDR; (iii) decreased binding affinity of the vitamin Szabo et al., nevertheless also demonstrated a decrease D-VDR complex to the VDREs (Figure 1 ).
of VDR [7] . What is the evidence that one or more mechanism Another possible explanation for these divergences, play a role in uraemia? If this were the case, hyperpara-is that the expression of VDR depends on the type of thyroidism would not be prevented, even if adequate parathyroid hyperplasia, which may be nodular or calcitriol levels can be obtained.
diffuse. Hyperplastic parathyroids of the nodular type contain substantially less VDR than glands of the Decreased binding of calcitriol to the VDR diffuse type [13] . Even if the parathyroid glands from the experiments by Szabo et al. contain a similar number of VDR, This issue has been studied repeatedly. In none of with or without renal failure, the normal upregulation these studies could a decrease of binding affinity be demonstrated.
in response to calcitriol is inverted in the uraemic condition [12] . 
Decreased binding affinity of VDR with VDRE
action is observed with respect to the differentiation of the promyelocytic leukemia cell line, HL-60, to In earlier studies based on DNA-cellulose chromato-differentiate (unpublished results). graphy it has been suggested that interaction of VDR with DNA was inhibited in chronic renal failure [11] .
Binding affinity of the hormone receptor for DNA was Conclusions also reduced when the receptor was preincubated with uraemic ultrafiltrate [16 ] . Again, these findings were End-stage renal disease is characterized by a state of not uniformly confirmed [17] .
relative calcitriol resistance. 
Glycaemia and the development of diabetic
non-diabetic subjects, and those subjects treated with nephropathy insulin or islet/pancreas transplantation both in rats [6] [7] [8] and in man [9] [10] [11] [12] . Although preceded by a series of observations documenting advanced lesions of the glomerulus in the diabetic patient [1, 2] , Ruth Østerby of Å rhus Euglycaemia and the prevention or reversal of University first emphasized in man the early develop-diabetic nephropathy ment of glomerular basement membrane (GBM ) widening and mesangial expansion [3, 4] . She and With animal models, islet transplantation or optimum colleagues measured these structures in successive renal insulin therapy altered the course of the structural and biopsies, demonstrating convincingly the progressive functional lesions of diabetic renal disease [6] [7] [8] . nature of diabetic renal disease, even early in its course. Applied to rodent models, the time for reversal encomFurthermore, she worked towards unifying the under-passed 2-6 months-a duration much shorter than the lying pathophysiologic mechanisms of diabetic neph-time for efficacy demonstrated in people; however, ropathy stressing the accumulation of basement-studies in rats must account for the short time span membrane-like material. Although widening of the available over the life of the rodent. This problem is GBM and expansion of the mesangium may not reflect especially complicated in diabetic rats because of the identical biochemical or biophysical processes, they do minimum of 6 months of diabetes necessary to establish evolve similarly in the diabetic environment-as most glomerular lesions [8] . Thus these time demands reflected by studies in identical twins in which GBM within an animal of relatively short life span reduce width and mesangial expansion were increased uni-the questions that may be answered. Nevertheless, formly in the diabetic twin [5] . Importantly, these much important work has been accomplished in morphometric measurements of glomerular lesions rodents demonstrating the feasibility of subsequent studies in man. Of importance are those issues raised normoglycaemia. The animal studies demonstrated of Bilous et al. [9] with pancreas transplantation on convincingly the fundamental efficacy of normoglycae-average 4-5 years after kidney transplantation indimia in preventing and/or reversing the lesions of dia-cated clearly that early lesions could be beneficially betic nephropathy.
altered by the establishment of euglycaemia. For prevention or reversal of early glomerular lesions
The question of reversing the more advanced mesin man, 4-5 years of optimal glycemic control were angial lesions was addressed with pancreas transplantanecessary to yield efficacy in patients with transplanted tion to type I diabetic patients with their own kidneys kidneys [9, 10] . The more advanced structural lesions and advanced diabetic nephropathy by both functional resisted reversal or amelioration with pancreas trans-and structural criteria [11, 12] . Of importance, the plantation alone, at least after the initial 5 years of mesangial expansion was marked, and of greatest follow-up [11] . Overall, these studies demonstrated interest concerning the reversibility of extra cellular quite convincingly that euglycaemia established at rela-matrix constituents, the GBM was widened greatly. tively early stages of disease greatly affected the devel-Thus any evidence of reversibility would emphasize opment and/or progression of human diabetic renal strongly that even very long-lived proteins in their disease.
native state or following post-synthetic modification With the large body of work on the progression of may return towards normal molecular structure and functional markers of diabetic nephropathy an array concentration following prolonged exposure to a of both structural and functional parameters of dia-normal or near-normal metabolic environment-best betic nephropathy may now be used to evaluate the estimated by HbA1c. With the long duration of diaefficacy of various therapeutic modalities. Specifically, betes in the recipients and their advanced renal lesions, the observations of reduction of albuminuria in the it was not surprising that the lesions remained Diabetes Control and Complications Trial (DCCT ) unchanged 5 years after pancreas transplantation, as [13] were elaborated in the DCCT nephropathy paper first reported [11] . Yet, in keeping with the prolonged [14] ; however, the relatively short duration of diabetes time course necessary for the development of glomerin the DCCT subjects (i.e. most being less than 5 years ular lesions and significant abnormalities in the renal at the start of the DCCT, relative to the 15-25 years function characteristic of this pancreas transplant of diabetes necessary to allow nephropathy to produce recipient population, the 10-year results demonstrated advanced lesions-see below) compromised opportun-a clear benefit of euglycaemia after pancreas transities to demonstrate improvement of other parameters plantation in reversing nearly all lesions [12] . of diabetic nephropathy (e.g. blood pressure and glomThe time course (5-10 years) of the response to erular filtration rate estimated by two different euglycaemia with pancreas transplantation reflects the techniques).
need to clinically implement optimal glycemic control over a course of years in each patient or patient population. Thus, intensive glycemic control or
Glomerular lesions: the course of development and
pharmaceutical agents directed specifically at the modthe time required for reversal erate-to-advanced functional and structural manifestations of diabetic nephropathy will require treatment Since the structural and functional lesions of diabetic for periods approaching a decade before any clear nephropathy evolve over the first 2-3 decades of benefit may be demonstrated. Alternatively these disease, macroalbuminuria (e.g. >300 mg/24 h) in type optimistic findings of reversibility of the advanced I diabetic patients will present during the second (and lesions compel those managing diabetic patients to later) decade(s) of disease. The increase in GBM width work as aggressively as possible to prevent the original becomes evident during the first 10 years followed by development and progression of the structural and a measurable expansion of the mesangium [3, 4, 15] . Of functional renal lesions of diabetes. importance, the expansion of the mesangium characterizes the lesions that threaten renal function. Therefore in those patients evolving to macroalbuminuria the GBM width and mesangial expansion will clearly reach References abnormal proportions as microalbuminuria progresses [16, 17] . before a clear benefit of intensive management became 785-800 apparent [13, 14] . Since a rising albuminuria reflects Introduction disease. The first identified renal lesion was amyloidosis in the patients with FMF who had persistent proFamilial Mediterranean fever ( FMF ) is an autosomal teinuria [4] . In 1955, Shwayri and Tutunji [8] reported recessive hereditary disease which primarily affects a case whereby a patient had abdominal and thoracic Jews, Armenians, Arabs and Turks [1, 2] . The disease pain ( FMF ) with synchronous gross haematuria, but was first outlined by Siegal in 1945 and characterized no tissue diagnosis was available. Furthermore, the by recurrent and self-limited attacks of fever, usually occurrence of microscopic haematuria during attacks, accompanied by peritonitis, pleuritis, arthritis or erybut sometimes also in no relation to them, has been sipelas-like erythaema [3] . The development of amyl-observed [5] . In 1970, Eliakim et al. analysed renal oidosis is the most common renal complication of manifestations of 106 patients with FMF and found FMF that leads inevitably to chronic renal failure that 12.3% had amyloidosis, while 21.7% had renal [4] [5] [6] [7] . The frequency of amyloidosis differs among lesions other than amyloidosis. Patients in the last various ethnic groups and depends on whether patients category clinically presented with transient or persistent are taking colchicine [1, 2] . It has been well documented haematuria and albuminuria, particularly during that the presence of amyloidosis determines the pro-attacks, and a variety of glomerulonephritides includgnosis of the disease. However, in addition to amyl-ing acute post-streptococcal glomerulonephritis and oidosis other renal lesions have been described in the Henoch-Schö nlein purpura (HSP) were found. patients with FMF and it seems that these renal lesions Histologically some of the kidney biopsies showed have been relatively neglected [6] [7] [8] [9] [10] [11] [12] [13] . mesangial proliferation, but no immunoflourescence studies were performed [7] . In 1982, Flatau et al.
showed focal mesangial proliferative glomerulo-
The spectrum of renal involvement other than nephritis in two patients who had FMF and HSP [13] .
amyloidosis in FMF
During the last decade more renal biopsies were performed in patients with FMF who had urinary findings. Soon after the first well documented cases of FMF A variety of non-amyloid glomerular diseases were were published it became apparent that renal involve-described. The presence of mesangial proliferation, IgM nephropathy, IgA nephropathy, focal and diffuse proliferative glomerulonephritis, mesangiocapillary glomerulonephritis, and rapidly progressive glomerulo-the glomerulus and facilitates the development of these non-amyloid glomerular diseases. nephritis were reported in patients with FMF even in the absence of amyloidosis [6, [9] [10] [11] [12] . In addition, some of the non-amyloid glomerular lesions described in the Conclusion patients with FMF were associated with vasculitis [6, 7, [12] [13] [14] . Furthermore, the coexistence of a variety
The observations reported from different countries of vasculitic syndromes with FMF was noted to be indicate that the patients with FMF are prone to more frequent than in general population [13, 14] . exhibit a variety of glomerular diseases other than amyloidosis. Although amyloid renal disease is definitely common in FMF patients, there are no good
Possible pathogenesis
epidemiological studies showing that non-amyloid glomerular diseases are also more frequent in the The biochemical basis of FMF is still unknown but patients with FMF than in the general population. An the gene responsible for the disease was cloned recently important source of confusion is the interpretation of by two independent teams [15, 16 ] . The gene product persistent albuminuria as a sign of amyloidosis in the called pyrin/marenostrin was reported to be a protein absence of histologic proof. It is pertinent to point out that is responsible for limiting the intensity of inflamthat the actual frequency of non-amyloid glomerular mation. It was suggested that FMF-associated mutalesions in patients with FMF depends largely on the tions and the resultant structural changes of the protein number of kidney biopsies performed in patients with interfere with the normal pyrin/marenostrin mediabnormal urinary findings. ated negative feed back mechanism, thus favouring
Colchicine treatment was clearly shown to ameliorthe onset and persistence of inflammation [15] [16] [17] .
ate the course of FMF and to prevent the development Although the identification of the FMF gene advanced of amyloidosis [1, 2] . A review of the literature reveals the understanding of the regulation of acute inflamthat some of the FMF patients were not taking regular matory responses, the pathogenesis of the disease is colchicine treatment when they developed non-amyloid still obscure. Based on clinical and laboratory findings glomerular diseases [5] [6] [7] [8] [9] [10] [11] [12] . It remains to be seen several pathogenetic mechanisms have been suggested.
whether regular colchicine treatment that prevents Circulating immune complexes, complement consumpacute attacks and amyloidosis, may prevent the develtion, increased concentrations of immunoglobulins opment of non-amyloid glomerular diseases in the during attacks and return to normal after the acute patients with FMF. Finally, it is important to emphasattacks support the notion that an immune reactant ize that non-amyloid glomerular diseases should be mechanism underlies FMF [6 ] . showed the effectiveness of a schedule based on alternmay be variable but a recent review of the available ating cycles of methylprednisolone and chlorambucil studies, including nephrotic and non-nephrotic every other month for 6 months. A first study compatients, reported that renal survival at 10 years was pared the effects of methylprednisolone and chloram-0.65 [1] . It is likely, however, that the prognosis is bucil and those of symptomatic treatment in patients even worse in nephrotic patients, as the risk of renal with IMN and nephrotic syndrome. At 10 years, 92% failure is correlated to the severity and the duration of of treated patients versus 60% of untreated controls proteinuria [2] . Nephrotic patients are also exposed to were still alive without dialysis. Treated patients spent an increased risk of cardiovascular death [3] as well 58% of their time without nephrotic syndrome versus as to intravascular thrombosis and other potential 22% of controls [5] . A second study compared methylcomplications [4] . Thus, although many clinicians still prednisolone and chlorambucil, and methylprednisoadhere to the dogma that IMN should not be treated, lone alone given at the same cumulative dose. At the it is our opinion that any treatment that is able to end of a mean follow-up of 54 months, 64% of patients modify the natural course of this disease in patients given methylprednisolone and chlorambucil versus with the nephrotic syndrome is welcome.
38% of patients given methylprednisolone alone were without nephrotic syndrome, the difference being significant [6 ] . In a third trial methylprednisolone and Treatment with corticosteroids and/or cytotoxic chlorambucil were compared with methylprednisolone agents alternated with cyclophosphamide [7] . The probability of attaining as a first event complete or partial remisCorticosteroids have been used in IMG for many sion of the nephrotic syndrome was similar (82 vs years. A meta-analysis of the available controlled trials 93%), the risk of relapse was also similar (30 vs 20%). concluded that, at least at the doses used in the few Thus, the use of steroids alternated with either chloravailable randomized trials, corticosteroids neither ambucil or cyclophosphamide may favour remission improve the probability of remission of proteinuria of the nephrotic syndrome and may protect renal nor protect from renal function deterioration [1] . function in the long term. It is worth rememberControlled studies showed that the administration of ing that in more than half of responders, remission cyclophosphamide or chlorambucil for 1 year or more of proteinuria develops weeks or months after the may cause consistent reduction of proteinuria in a treatment was completed [5] [6] [7] .
Results with cyclosporin
Correspondence and offprint requests to: Prof. Claudio Ponticelli, In the last few years cyclosporin has been used in a 
number of proteinuric glomerular diseases including
those patients who do not have contraindications to first report of De Santo et al. [8] reported complete remission of proteinuria in four of five patients who the use of cyclosporin it is mandatory to monitor plasma creatinine carefully during treatment in order had failed to respond to a 6-month therapy with methylprednisolone and chlorambucil. Unfortunately to prevent the development of so-called cyclosporin nephropathy which consists of arteriolar changes and the follow-up was quite short; moreover it is possible that in some patients remission was a late response to irreversible interstitial fibrosis. The higher the increase in plasma creatinine under cyclosporin the higher the methylprednisolone and chlorambucil. Meyrier [9] reported the data of the Sandoz file. Complete remis-risk of irreversible nephrotoxicity. The risk of cyclosporin nephropathy is about 10-12% for increases of sion was seen in 14 of 73 adults treated with cyclosporin and partial remission was obtained in another 18 plasma creatinine of about 30%, it is around 50% when plasma creatinine doubles over the baseline and patients. Gausch et al. [10] reported a decline of proteinuria from a nephrotic to a non-nephrotic range approaches 100% for higher increases of plasma creatinine [14] . To be on the safe side, whenever plasma 2-4 weeks after treatment in 10 of 14 patients with IMN. Rostoker et al. [11] obtained complete remission creatinine rises by more than 30% over the baseline, cyclosporin should be stopped for at least 1 month. of proteinuria in four of 15 nephrotic patients treated with cyclosporin and another seven had reduction of Administration of the drug may be resumed if plasma creatinine returns to normal or to values not higher proteinuria from a nephrotic to a non-nephrotic range. In a cross-over study, Ambalavanan et al. [12] assigned than 10% over the baseline. 14 patients to receive a 3-month course with cyclosporin or enalapril. Enalapril reduced blood pressure but Practical recommendations had no effect on proteinuria; cyclosporin showed a reduction of proteinuria of more than 50%. After stopping cyclosporin proteinuria rose to pre-treatment Cyclosporin should probably be considered as a second-line treatment in patients with MN and severe values but reduced again when cyclosporin was reintroduced. Cattran et al. [13] assigned 17 patients with nephrotic syndrome. In fact, those patients who respond to a 6-month course with methylprednisolone severe proteinuria and/or renal dysfunction to placebo or to cyclosporin for 1 year. Proteinuria significantly and either chlorambucil or cyclophosphamide may maintain remission for years or even indefinitely. There decreased in the treated group; moreover the decline in creatinine clearance was more rapid in the placebo is good evidence that the responders maintain normal renal function over time. Patients who relapse often than in cyclosporin-treated group. Taken together, these data show that cyclosporin may be effective in respond similarly as during the first course. It is therefore rational to retreat them if they had a good favouring the remission of the nephrotic syndrome in 50 to 60% of patients. Reduction of proteinuria usually response to a first treatment. On the other hand, more prolonged treatment is presumably unsafe in those occurs within a few weeks, so that if urinary protein excretion does not modify within 3-4 months it is patients who did not respond to a 6-month course of steroids alternated with an alkylating agent. Thus, if unlikely that cyclosporin will be effective. As in other glomerular diseases, the nephrotic syndrome reappears no response is observed, one should consider administration of cyclosporin. We suggest, however, waiting in most cases after the drug is stopped. With the exception of the small trial conducted by Cattran et al., at least 12 months after the cessation of the steroidcytotoxic treatment before beginning treatment with little information is available on the effects of cyclosporin on prevention of renal functional deterioration. cyclosporin, in order to avoid an useless treatment for late-responders. Moreover, it is preferable that patients However, when repeat biopsy was performed, as in the study of Ambalavanan et al. [12] , it was shown that are not submitted consecutively to two immunosuppressive treatments in order to reduce the risk of cyclosporin did not prevent continuing autoantibody formation in MN. It is not clear whether the addition side-effects.
The starting doses of cyclosporin should not exceed of small doses of corticosteroids improves the effectiveness of cyclosporin in patients with IMN.
4 mg/kg/day with the new microemulsion cyclosporin, which has a better bioavailability than the old formulation. Blood levels should be checked in order to assess
Problems with the use of cyclosporin
whether the patient is a good or a poor absorber of cyclosporin. Initially, through blood levels may be kept between 75 and 200 ng/ml, as assessed by the monoCyclosporin is a potentially nephrotoxic drug and may expose the patient to hypertension and to the risk of clonal assay. Once again the need of a careful monitoring of renal function and blood pressure under progressive renal failure. This risk is dose-dependent and age-dependent [14] . It is particularly increased in cyclosporin treatment must be stressed. If no reduction of proteinuria is seen within 3 months cyclosporin may patients with elevated plasma creatinine and with tubulointerstitial lesions at initial renal biopsy [15] . Thus be stopped, it being unlikely that the drug would exert an antiproteinuric effect with a more prolonged adminpatients with a creatinine clearance lower than of a randomized study with methylprednisolone and chlorambuistration. In the case of remission we try to reduce cil in membranous nephropathy. Kidney Int 1995; 48: 1600-1604 slowly the doses (0.5 mg/kg every month) down to a 6. Ponticelli C, Zucchelli P, Passerini P, Cesana B and the Italian maintenance dosage of 2.5-3.0 mg/kg per day, and Introduction interstitium which may contribute to the development of glomerulosclerosis [1, 2] . The benefits of reducing The activity of the Renin-Angiotensin System (RAS ) RAS activity in patients with diabetic nephropathy may contribute to progression of renal diseases as a and non-diabetic renal disease have been demonstrated result of its effect on arterial blood pressure and in prospective trials in which angiotensin-I-converting intraglomerular pressure. In addition, there is evidence enzyme inhibitors (ACEI ) were shown to have a that RAS may also act via non-haemodynamic mechrenoprotective effect greater than that afforded by anisms such as mesangial cell mitogenesis and by strict blood pressure control alone [3, 4] . With the influencing the balance of accumulation and degradaintroduction of angiotensin II receptor antagonists (AT 1 -ra), there is now a choice as to the method of between ACEI and AT 1 -ra [5] [6] [7] . We would like to ate with the degree of attenuation of GFR reduction. Increased bradykinin levels may also have important add to the debate regarding the merits, or otherwise, of these drugs in clinical practice and highlight the non-haemodynamic benefits by increasing the activity of metalloprotinases which degrade extracellular potential role of molecular biology in future clinical decision making.
matrix. In addition to actions on AT 1 receptors, AII also stimulates AT 2 receptors. It may be premature to
Limitations of ACE inhibition
speculate on the importance of AT 2 receptor stimulation as their clinical role in healthy humans and disease states has not been fully elucidated. In healthy humans ACE is not specific to the RAS and is involved in the breakdown of several other products, such as brady-AT 2 receptor expression in the kidney appears to be low. Stimulation of these receptors does, however, kinin. Elevated levels of bradykinin is probably the mechanism for the ACEI-related side effects such as appear to have an effect of lowering blood pressure (possibly by a central mechanism involving reduction cough and anaphalactoid reactions [8] . Cough occurs no more frequently with AT 1 -ra than with placebo [9] . in sympathetic nervous system activity) which may contribute to the antihypertensive effect of AT 1 -ra. While ACE is the principal method by which angiotensin I (AI ) is converted to angiotensin II (AII ), This dual antihypertensive action may limit the dose of AT 1 -ra such that maximally tolerated doses (as this step can also be carried out by other enzymes. Non-ACE formation of AII is not blocked by ACEI judged by blood pressure response) may be below the doses required to produce additional renoprotection and may be important in maintaining tissue AII levels. In the heart, for example, cardiac chymase activity (resulting from blockade of the 'local' RAS ). Within the kidney AT 2 stimulation has an antinatriuretic effect contributes to formation of AII and is unaltered by ACEI. Indeed, the effect of the non-ACE pathways and may reduce degradation of extracellular matrix leading to accumulation in the glomerulus [7, 16 ] . The may actually be exaggerated during treatment with ACEI as a result of high levels of AI and AT 1 receptor local effect of AT 1 -ra is dependent upon the distribution of AII receptor subtypes and considerable interup-regulation. It is not clear, however, if the non-ACE conversion of AI to AII is of clinical significance species variation in distribution has been demonstrated [17] . As a consequence of this the effects of AT 1 -ra although there is evidence that AII levels gradually rise with time after starting ACEI [10] . AT 1 -ra, by seen in animal studies, e.g. regression of left ventricular hypertrophy [18] , may be more difficult to demonstrate contrast, offer the possibility of 'total blockade' of the effects of AII at the AT 1 receptor that cannot be in humans as a result of the increased expression of AT 2 receptors in human myocardium [19, 17] . achieved by ACEI.
Limitations of AT 1
receptor blockade ACEI and AT 1 -ra alone or in combination?
AT 1 -ra should not be seen solely as an alternative to The results of prospective clinical trials evaluating the role of AT 1 -ra in renal disease are not yet available ACEI. Some patients do not achieve satisfactory blood pressure control (or renoprotection) on maximal doses and their efficacy, in this respect, remains unproven. Similarities in the mode of action (i.e. reduced AII-of ACEI and the combination may, therefore, allow further RAS blockade while overcoming some of the mediated activity) of AT 1 -ra and ACEI may suggest that their clinical effects will be comparable. There are concerns of using either agent in isolation. Additional RAS blockade has been confirmed by a further increase several reasons, however, why this may not be the case. In rats the beneficial effect of ACEI on renal in plasma renin levels [20] and seems not to have adverse clinical or biochemical effects. Animal models, haemodynamics is partly through bradykinin-mediated dilatation of the efferent arteriole [11] . This accounts however, have not found the combination to be better than either drug alone [21] . Further work is required for the fall in intraglomerular pressure (and the initial fall in glomerular filtration rate [GFR] and protein to study the expression of AT 2 receptor in disease states and to examine the possibility that some of the excretion [12] ) after ACEI. In animal models AT 1 -ra do not appear to produce the fall in proteinuria that actions of AT 1 -ra may be due to AT 2 receptor stimulation. If the actions of AT1-ra were found to be is observed with ACEI although they have a similar effect on the attenuation of glomerulosclerosis [13] . In mediated partly by AT 2 receptor stimulation then the reduction in angiotensin II levels caused by ACEI may the absence of salt and water depletion, AT 1 -ra do not have this acute haemodynamic effect on the human be a possible explanation for the failure to demonstrate clinical synergy by concomitant use of both agents. kidney and do not produce an initial fall in GFR [14, 15] . A study of 13 patients did, however, observe a reduction in proteinuria with AT 1 -ra despite no Trials involving AT 1 receptor antagonists change in GFR [14] . The relative contribution of haemodynamic and non-haemodynamic mechanisms to the renoprotective effect of ACEI is not known, A recently published trial comparing AT 1 -ra and ACEI in patients with cardiac failure [ELITE] suggested that although the reduction in proteinuria appears to correl-AT 1 -ra are better tolerated [22] . There was also a in patients with progressive renal disease unless they are not tolerated. It is possible that AT 1 -ra may offer suggestion of superior efficacy of AT 1 -ra although this may be explained partly by a difference in compliance additional advantages in some patients or that synergy exists between the two agents, but this view will remain if ACEI were associated with increased side-effects. A study on the effect of AT 1 -ra on cardiovascular entirely speculative unless proper trials are conducted. Despite the results of the ELITE study [22] , the end-points is underway (Losartan Intervention for Endpoint Reduction-LIFE ) as are separate studies uncertainty regarding the use AT 1 -ra in cardiovascular disease mirrors that of renal disease. This issue is into the effects of Ibersartan (by the Collaborative Trial Group) and Ibersartan ( The RENAAL study) in obviously of relevance to the nephrologist in view of the spectrum of cardiac disease that accompanies delaying progression to end-stage renal failure in patients with type II diabetes and established nephro-chronic renal failure, such as left ventricular hypertrophy and cardiac failure, which provide multiple pathy. The Ibersartan and the Losartan studies will also evaluate the effect of AT 1 -ra on cardiovascular indications for manipulation of RAS. Despite their renoprotective effect, previous studies on ACEI [3, 4] events in a group at high risk of developing cardiovascular complications but they do not consider the effect have not shown an overall reduction in mortality and this issue needs to be addressed in addition to renoof preventing the progression from microalbuminuria to overt nephropathy, as was shown recently for ACEI protection in studies comparing AT 1 -ra and ACEI. [23] . Unless trials directly comparing AT1-ra to ACEI (±combined treatment) are carried out, the indication for AT 1 -ra over ACEI, with the exception of References intolerance to the latter, will remain elusive. Once upon a time, when no effective treatment was controlling blood pressure is an essential part of dialysis treatment and that this could be achieved in the available for hypertension, the conviction prevailed that high blood pressure was an inescapable fate and large majority of patients without the use of drugs, by salt restriction and ultrafiltration during dialysis that lowering it might even be harmful. German doctors found a nice expression for this comforting view: sessions.
In the following years an unexpected development 'Erfordernisshochdruck' (hypertension of necessity).
Since then, the devastating effects of hypertension was observed in the dialysis community: cardiovascular mortality remained unacceptably high and continued have been amply documented. What is more, large trials have shown such decreases in morbidity and to be the leading cause of death among dialysis patients. Hypertension also persisted in the majority mortality after anthypertensive treatment, that this may be considered one of the most important successes of patients, despite the increasing use of ever more sophisticated antihypertensive drugs. Nevertheless relaof modern medicine.
tively little attention is given to this vital subject. Textbooks on dialysis devote not more than 5-8% of Hypertension in the uremic patient their pages to hypertension and cardiac complications. In addition, a change of opinion among investigators can be observed in recent years, on two most crucial In 1960 Belding Scribner initiated chronic haemodiasubjects. lysis treatment for terminal renal failure, until then a fatal condition. Incidentally, his first patient also had malignant hypertension, which was cured by controlIs hypertension associated with poor survival? ling his extracellular volume. It became clear, that
The first is that the importance of hypertension as a Secondly, it is being suggested that the pathophysio-heart damage is present. This has been a plausible explanation for the J curve. The fact that with multivarlogy of hypertension in dialysis patients is different from essential hypertension and that unknown factors, iate analysis, serum albumin level had a very significant relation with survival while the low RR of hypertension special for the uremic state, play a dominant role. In particular the pathogenetic role of expansion of blood lost the significance seen with univariate analysis [6 ] , may also suggest that the normotensive patients were volume and extracellular volume, once widely accepted, is again being doubted. not generally in good shape. Unfortunately, the absence of any data (e.g. chest X-ray and echocardioAlthough these two matters are closely related, particularly when it comes to prevention and treatment, I gram) in this study preclude validation of these speculations. Anyhow, the assumption that a simple linear will only address the first one here.
The suspicion that hypertension has little to do with relationship between blood pressure and mortality is also present in short-term studies would neglect the the poor prognosis of dialysis patients is indeed widespread, particularly in the US. As a result, not a single complicated nature of these problems.
Another remarkable fact in Salem's study [6 ] is that paper or session devoted to blood pressure control was accepted at the NKF meetings or at the ISN congress most of the hypertensive patients (81.5%) used antiin the past year [4] . As an extreme consequence, the hypertensive drugs, while none of the normotensives Health Care Financing Administration withdrew blood took any. This implies that the antihypertensive drugs pressure data from the Haemodialysis Core Indicator were completely ineffective, not a single patient thus data set. The reason for this unfortunate decision is treated becoming normotensive. Despite this, the probably the paucity of congitudinal studies demon-author speculates that the drugs may have improved strating that blood-pressure control reduces morbidity the prognosis by ameliorating excessive blood presand mortality [5] .
sure swings. Indeed in some studies a clearcut relationship That drug treatment in haemodialysis patients between blood pressure and survival was not found. decreases blood pressure variation has never been Others, who did observe increased mortality with high demonstrated, while the opposite is reported in most blood pressure levels also reported more mortality in textbooks. patients with blood pressure below a certain point (so As remarked earlier, studies proving an adverse called J curve) [3] .
effect of hypertension and an improvement of proElsewhere in this issue Salem reports a 2-year multi-gnosis with adequate treatment are few. In my opinion centre follow-up on 649 haemodialysis patients [6 ] . this is related to the fact that drug treatment is not Surprisingly, hypertension was associated with a better often successful in dialysis patients as is also apparent survival.
in this study [6 ] . This raises intriguing questions. Is hypertension only harmful without renal disease but beneficial in Is volume control the answer? dialysis patients? Do we witness a rebirth of the 'Erfordernisshochdruck' concept? It is obviously not
In contrast, an impressively long survival, far exceeding possible to explain the existing controversies from the any other reported series, was achieved in a large available data in the literature, but commenting on group treated without drugs but ( like the historic first some details of this study may be helpful. patient) with meticulous volume control [8] . That such In a previous report on the same patients after a large difference would be due to ethnic differences 1-year follow-up [7] , the relative risk ration (RR) of seems highly unlikely. Why should cardiovascular hypertension vs normotension was 0.38 for black pathophysiology be different? Reluctance to accept patients (who constituted 89% of the group) but in that it is indeed possible to treat hypertension and whites this risk was 3.38 a 9-fold difference. In the thereby prevent cardiovascular complications by present 2-year follow-up, this difference has decreased adequate volume reduction may stem from the presentbut blacks were still better off with hypertension (RR day preoccupation of the medical profession with 0.56), while whites had a RR of 1.4. Still the suggestion 'controlled trials'. Some results, particularly when they remains that hypertension during dialysis treatment are as striking as those of the Tassin investigators, and may not be harmful in blacks, while it is well known in addition fit with known (but neglected) pathophysithat in the absence of renal disease hypertension is ological principles [9] , do not need a control group. much more devastating in blacks than in whites.
To include a control group would imply leaving a large Indeed, blacks had a better survival in this study.
number of patients untreated for some years, which would be unethical.
Paradoxically better survival in patients with high
When investigators still call for prospective trials it blood pressure-are confounding factors the should first be established which treatment is applied.
explanation?
It is not at all certain that hypotensive drugs can bring down blood pressure for long periods in hemodialysis patients. In contrast this goal can be achieved by How can these apparent contradictory facts be reconciled? Hypertension is a long-term process and observa-volume control, but this method needs intense, ongoing individual care for the patients, for which much more tions during dialysis describe a relatively late phase. In addition blood pressure often decreases when severe doctor's time is needed than is customary [10] . 
Conclusion
on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379-1385 4. Scribner B. Reducing mortality in dialysis patients: why does In conclusion it would be regrettable if readers
